Mec hanism of Qingzhi Huayu Formula in Treating Coronary Heart Disease with Dyslipidemia Based on Metabolomics and Network Pharmacology

ZHANG Minghao; WANG Tian; LIU Milin; QU Huiyan; YANG Tao; DAI Enrui; ZHOU Hua

doi:10.12102/j.issn.1672-1349.2025.23.001

Abstract：Objective:To explore the pharmacological mechanism of Qingzhi Huayu Formula in treating coronary heart disease with dyslipidemia by integrating serum metabolomics and network pharmacology techniques.Methods:Thirty-three patients with coronary heart disease complicated dyslipidemia were randomly divided into experimental group(15 patients)and control group(18 patients).The patients in experimental group received Qingzhi Huayu Formula granules orally with standard Western medicine treatment,while the patients in control group received the placebo combined with basic Western medicine treatment.After 8 weeks of treatment,fasting blood was collected from patients in the two groups,and serum metabolomics techniques combined with pattern recognition methods were used to identify endogenous differential metabolites and related metabolic pathways.The network pharmacology technology was used to explore the potential active ingredients,key targets,and biological pathways involved in the Qingzhi Huayu Formula.Results:The results of serum metabolomics showed that there were six differential metabolites between the two groups,involving multiple metabolic pathways such as fatty acid metabolism,arginine metabolism,proline metabolism,linoleic acid metabolism,nucleotide metabolism,purine metabolism,and tryptophan metabolism.The network pharmacology results revealed 85 potential active ingredients in the Qingzhi Huayu Formula,as well as multiple direct targets and biological signaling pathways associated with hyperlipidemia.Molecular docking technology showed that the binding force between the active ingredient baicalein and the nitric oxide synthase 3(NOS3)target was the strongest.Conclusion:Qingzhi Huayu Formula can intervene coronary heart disease complicated with dyslipidemia through multiple components,targets,and pathways.